Imatinib, a drug used to treat chronic myeloid leukemia (CML), induces TAp73 (a p53 family member) phosphorylation and localization to PML NBs in a p38- and PML-dependent manner in CML cells (Liu et al., 2009). Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.